Lima, Peru

Via Libre

HIV Infections

Infections

Acquired Immunodeficiency Syndrome

Communicable Diseases

Lenacapavir

Apricitabine

nucleoside

Avexa

Fred Hutchinson Cancer Center (FHCC)

Gilead Sciences

University of Minnesota (UMN)

Kirby Institute

NGO Via Libre

Universidad Peruana Cayetano Heredia

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Via Libre | Lima, Peru

Site insights

Work at this site?

Active trials

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

Trial sponsors